Allogene Therapeutics secures dual FDA designations for its allogeneic CAR-T candidate, accelerating development and review pathways.
Allogene Therapeutics (ALLO) shares climbed after the FDA designated its cell therapy candidate, cemacabtagene ansegedleucel (cema-cel), as a Regenerative Medicine Advanced Therapy (RMAT) and granted Fast Track status. The designations aim to expedite development and review of the allogeneic CAR-T therapy for potential market approval.
The RMAT designation is reserved for therapies addressing serious conditions with preliminary clinical evidence of substantial improvement over existing treatments. Fast Track status facilitates more frequent interactions with the FDA to accelerate the approval process. Allogene’s cema-cel targets hematologic malignancies, a competitive area in oncology.
The market reaction reflected investor optimism, with ALLO shares rising on the announcement. The dual designations could shorten the therapy’s path to commercialization, positioning Allogene as a key player in the cell therapy space.